| ￥4900 | |
| Z05329-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 70.3 kDa (GARP(Y137H&S138G&G139N))&41.4 kDa (Latent TGF Beta 1) | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 75-80 kDa (GARP(Y137H&S138G&G139N))&15 kDa&43-47 kDa (Latent TGF Beta 1) based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of GARP (Y137H&S138G&G139N) &Latent TGF Beta 1 Complex, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
GARP (Y137H&S138G&G139N) &Latent TGF Beta 1 Complex, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | GARP&Latent TGF Beta is a complex found on surface of many types of cells. In Tregs, GARP is involved in TCR-mediated activation of Latent TGF-β and thus promoting secretion and activation of TGF-β. Integrin αvβ8 on the surface of immune cells and other cells recognizes RGD in LAP, resulting in the release of mature TGF-β from the TGF-β&GARP complex. |
| Synonyms | LRRC32; GARP; LAP; TGF-beta-1; LRRC32&TGF-beta 1; LRRC32&TGFB1; TGF-β-1; LRRC32&TGF-β 1; GARP&Latent TGF Beta; GARP&Latent TGF Beta 1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
